MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases
August 10 2021 - 2:30PM
Business Wire
Patent protects Supera-CBD, shown to be 7-8X
more effective than plant-derived CBD in reducing enzymes that play
a key role in pain, inflammation, and neurodegeneration
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the
Company”), a clinical stage pharmaceutical company committed to
extending healthy lifespan by focusing on developing two
therapeutic platforms, today announced that the United States
Patent and Trademark Office (USPTO) has issued U.S. Patent No.
11,085,047 titled “Synthetic Cannabinoid Compounds for the
Treatment of Substance Addiction and Other Disorders.”
The patent protects the Company’s drug candidate Supera-CBD, a
synthetic cannabidiol derivative that targets cannabinoid receptor
type 2 (CB2) for the treatment of neuroinflammatory and
neurodegenerative diseases. It also protects pharmaceutical
compositions containing the Supera-CBD compound. Supera-CBD is
being developed to address anxiety, chronic pain, addiction, and
seizures, and is on a path toward human clinical trials as a
therapy for epilepsy, followed by chronic pain.
“Supera-CBD has the potential to address the significant unmet
need for medications to treat stimulant addictions, specifically
cocaine, methamphetamine and opioids, which currently have no
approved treatment,” said Chris Chapman, M.D., President, Director
and Chief Medical Officer of MyMD. “This first patent for
Supera-CBD will support our discovery efforts as we move forward
with this platform as a major focus for our Company. It also
diversifies and strengthens our growing intellectual property
position, which already contains 11 granted patents for our MYMD-1
drug platform.”
Supera-CBD is a non-toxic, synthetic, preclinical cannabidiol
derivative that has been shown in in vitro studies to be
approximately 7-8x more effective than plant-derived CBD in
inhibiting MAO-A and MAO-B enzymes, and more than 3x more effective
than plant-derived CBD in inhibiting CB2. These superior efficacies
enhance Supera-CBD’s therapeutic potential to treat pain,
inflammation, and neurodegeneration, as well as substance
addiction.
“Supera-CBD shows great promise that it can provide all the
benefits of plant-based CBD, at a stronger and more efficient
level,” said Adam Kaplin, M.D., Ph.D., Chief Scientific Officer for
MyMD. “We are eager to see this drug move forward to help the many
who have long-awaited the relief that we believe it can provide. By
addressing an unmet need for pharmaceutical cannabinoids,
Supera-CBD is positioned to become a prescription drug alternative
to unregulated CBD.”
About MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) is a clinical stage
pharmaceutical company committed to extending healthy lifespan in
humans by focusing on developing two therapeutic platforms. MYMD-1
is a drug platform based on a clinical stage small molecule that
regulates the immunometabolic system to control TNF-α and other
pro-inflammatory cytokines. MYMD-1 is being developed to treat
autoimmune diseases, including those currently treated with
non-selective TNF-α blocking drugs, and aging and longevity. The
Company’s second drug platform, Supera-CBD, is based on a novel
synthetic derivative of cannabidiol (CBD) that targets numerous key
receptors including CB2 and opioid receptors and inhibits monoamine
oxidase. Supera-CBD is being developed to address the rapidly
growing CBD market, that includes FDA approved drugs and CBD
products not currently regulated as a drug. For more information,
visit www.mymd.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release may contain forward-looking statements. These
forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause actual results,
performance or achievements to be materially different from any
expected future results, performance, or achievements.
Forward-looking statements speak only as of the date they are made
and none of MyMD nor its affiliates assume any duty to update
forward-looking statements. Words such as "anticipate," "believe,"
"could," "estimate," "expect," "may," "plan," "will," "would'' and
other similar expressions are intended to identify these
forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements include, without limitation: the timing
of, and MyMD’s ability to, obtain and maintain regulatory approvals
for clinical trials of MyMD’s pharmaceutical candidates; the timing
and results of MyMD’s planned clinical trials for its
pharmaceutical candidates; the amount of funds MyMD requires for
its pharmaceutical candidates; increased levels of competition;
changes in political, economic or regulatory conditions generally
and in the markets in which MyMD operates; MyMD’s ability to retain
and attract senior management and other key employees; MyMD’s
ability to quickly and effectively respond to new technological
developments; MyMD’s ability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary
rights of others and prevent others from infringing on MyMD’s
proprietary rights; and the impact of the ongoing COVID-19 pandemic
on MyMD’s results of operations, business plan and the global
economy. A discussion of these and other factors with respect to
MyMD is set forth in the Quarterly Report on Form 10-Q for the
quarterly period ended March 31, 2021, filed by MyMD on May 18,
2021. Forward-looking statements speak only as of the date they are
made and MyMD disclaims any intention or obligation to revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210810005909/en/
Investor Contact: Robert Schatz (646) 421-9523
rschatz@mymd.com www.mymd.com
Media Contact: Will Johnson 201-465-8019
MYMD@antennagroup.com www.antennagroup.com
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MyMD Pharmaceuticals (NASDAQ:MYMD)
Historical Stock Chart
From Sep 2023 to Sep 2024